Moving drug discovery further, faster: SeqImmune - an innovative high velocity discovery engine leveraging the new ATX-GKH Hyperimmune Transgenic Mouse Platform

In this drug discovery environment, the drug discovery community faces numerous challenges bringing a new biologic to patients who need them. Time is a critical factor that contributes heavily on the probability of the success of a new biologic drug. Cost is another critical factor as small and medium companies with capital constraints are the major innovative engine in discovery phase. Alloy Therapeutics is a drug discovery partner that is expediting the path to the clinic through continuous innovation and partnerships. Alloy recently launched SeqImmune, a high-velocity antibody drug discovery workflow dramatically reducing optimized around Alloy’s ATX-Gx human transgenic mouse platform now now includes the use of ATX-GKH human transgenic hyperimmune mouse offering fast, robust response, and a deeper diversity that is ideal for any target. In partnership with Alloy’s Translational Research team and Wheeler Bio for Portable CMC(™), a partner has the potential to reach IND much faster. In this talk, we’ll highlight some of the key innovations that enables such a rapid path through discovery, reveal strategies for maximizing diversity with ATX mouse strains and highlight the partnerships and case studies to demonstrate the value of engaging a true drug discovery partner. Let’s move drug discovery further, faster.